Reveal LINQ Registry

- Subject or legally authorized representative provides written authorization and/or consent per institution and geographical requirements.

- Subject is intended to receive or be treated with the have a Reveal LINQ ICM inserted in the next 30 days.

- Patient enrolled before or on the same date of insertion of the Reveal LINQ ICM

- Subject consent prior to ICM insertion

- Subject who is, or is expected to be inaccessible for follow-up

- Subject with exclusion criteria required by local law

- Subject is currently enrolled in or plans to enroll a concurrent study that may confound the results of this study. Co-enrollment in any concurrent drug and/or device clinical study (including registries) requires approval of the study manager or designee.